Introduction
Sodium Butyrate is one of the most relevant active ingredients in nutraceutical solutions dedicated to intestinal health. As the salt form of butyric acid, it represents one of the main energy sources for colonocytes and plays a central role in maintaining intestinal barrier integrity.
Its use is well established in gastrointestinal, metabolic, and immunomodulatory applications, with growing scientific interest also in the modulation of the gut–brain axis.
However, the formulation of Sodium Butyrate is strongly limited by severe sensory issues and by the need for proper protection along the gastrointestinal tract.
In this context, the proprietary and patented MATRIS® technology makes it possible to overcome these limitations through a functional microencapsulation approach specifically designed for taste masking and gastro-protection.
Properties and application fields of Sodium Butyrate
Sodium Butyrate performs key functions at the intestinal level:
- Energy support for colonocytes
Primary energy source for epithelial cells of the colon. - Maintenance of intestinal barrier integrity
Contributes to the support of epithelial structure and function. - Modulation of intestinal balance
Used in nutritional protocols for gastrointestinal wellness. - Gut–metabolism and gut–brain axis
Subject of growing scientific interest due to its systemic interactions.
Formulation challenges of Sodium Butyrate
Despite its high nutraceutical value, Sodium Butyrate presents several limitations:
- Extremely unpleasant odor and taste, compromising compliance and adherence to treatment protocols
- Early release in the gastric environment, potentially causing irritation and reduced delivery to the colon
- Difficult integration in high-dose solid formulations
- Negative impact on the perception of the finished product
These factors clearly highlight the need for a technological system capable of protecting the active ingredient while improving its acceptability.
IPS innovation: Sodium Butyrate MATRIS®
Sodium Butyrate MATRIS® is produced through direct microencapsulation of the active ingredient using proprietary and patented MATRIS® technology, designed to optimize the behavior of the ingredient along the gastrointestinal tract.
Key technological benefits include:
- Effective taste masking, with a drastic reduction of odor and taste impact
- Enhanced gastro-protection, thanks to pH-dependent membranes that contribute to release modulation and protection of the active in the gastric environment
- Improved gastrointestinal tolerability
- Enhanced stability and industrial processability
In both available versions (Taste Masking – TM – and Gastro-Protected – GP), the coating system is designed to reduce the unpleasant organoleptic impact and induce release modulation without altering the nature of the active ingredient.
Scientific evidence
The nutraceutical value of MATRIS® technology is supported by preclinical studies conducted on advanced in vitro 3D models and human intestinal and gastric organoids, performed on several active ingredients formulated using the same technological platform.
Observed benefits include:
- improved interaction with the intestinal epithelium
- reduced impact on gastric membranes
- improved tolerability
- more gradual and controlled release
- increased bioaccessibility and consequently improved effectiveness
Across these studies, results consistently show similar outcomes attributable to MATRIS® technology itself, which therefore represents the key factor determining the gastrointestinal behavior of the microencapsulated active ingredient.
Formulations and applications
Sodium Butyrate MATRIS® is an optimal and versatile solution for developing the following dosage forms:
- capsules
- tablets
- sachets and stick packs
- single-dose vials with dosing cap
- SmarTTabs®, technological innovation by IPS for direct compression, preserving the release profile and MATRIS® characteristics
This versatility enables the development of advanced intestinal-health formulations with improved sensory tolerability.
Conclusion
Sodium Butyrate is a strategic active for intestinal health, yet strongly limited by sensory issues and early release challenges.
With Sodium Butyrate MATRIS®, IPS applies its microencapsulation technology to deliver a more tolerable, protected, and formulation-ready ingredient.
The MATRIS® platform further confirms the role of the SURACTIVES® division of IPS as a technology provider in the design of high-performance nutraceutical ingredients, capable of transforming critical actives into advanced industrial and functional solutions.
Note: This article is provided for informational purposes only and does not substitute professional medical advice.
